Dan is responsible for Lumanity’s European real world evidence (RWE) strategy and ensuring its alignment with the broader global strategy. He supports the team’s M&A and partnership activities, as well as strategic marketing and growth initiatives and works with clients to help ensure they get the right balance between cost, quality, and timeliness for their investment in real world data (RWD).
Dan’s career started with 15 years at major consulting houses in healthcare and pharmaceutical strategy. His last 8 years were at IQVIA focusing on RWD and how it can be used as a “common language” to connect all healthcare stakeholders and enable evidence-based insights to drive better decision making. Dan worked with many of the major pharma companies during this period helping them to optimize their investment in RWD both for individual studies and as a strategic asset.
He established the RWD Leader’s Forum which brings together senior executives from 21 pharmaceutical companies in a non-competitive environment to discuss and publish on the key challenges facing the evolution of RWD as it moves into the mainstream.
Dan holds a Masters in Biochemistry from Oxford University.